Fecal Calprotectin 491 µg/g: Interpretation and Management
A fecal calprotectin of 491 µg/g indicates active intestinal inflammation and requires endoscopic evaluation to assess disease activity before making treatment decisions. 1
What This Level Means
Your calprotectin level of 491 µg/g is significantly elevated and falls well above the critical threshold of 150 µg/g used to define active inflammation. This level strongly suggests active mucosal inflammation in your gastrointestinal tract 1.
Context-Specific Interpretation:
If you have established Crohn's disease or ulcerative colitis:
- This level indicates active disease requiring intervention
- At 491 µg/g, you have approximately 76% probability of having endoscopically active inflammation 1
- The AGA 2023 guidelines specifically state that levels >150 µg/g warrant endoscopic assessment rather than empiric treatment changes 1
If you don't have a diagnosis yet:
- Levels >250 µg/g strongly suggest inflammatory bowel disease or other significant intestinal pathology 2
- This warrants colonoscopy to identify the source of inflammation 3
- Rule out gastrointestinal infections (particularly Clostridioides difficile) before attributing this to IBD 1
Immediate Next Steps
1. Stool Testing for Infections
Before proceeding with endoscopy or treatment changes, obtain stool cultures for enteric pathogens and C. difficile testing, as calprotectin is not specific for IBD and can be elevated with infections 1.
2. Endoscopic Evaluation
You need colonoscopy (with ileoscopy if Crohn's disease is suspected) to:
- Confirm the presence and severity of mucosal inflammation
- Guide appropriate treatment decisions
- Avoid the risk of inappropriate treatment escalation based on biomarkers alone 1, 4
The 2023 AGA guidelines explicitly recommend against empiric treatment adjustment based solely on elevated biomarkers, even at your level 1.
3. Timing Considerations
If you are symptomatic:
- Proceed with endoscopy promptly
- Consider biomarker reassessment every 2-4 months during active treatment 1
If you are asymptomatic but have known IBD:
- Endoscopy is still recommended, though you could consider repeat calprotectin in 3-6 months if endoscopy was recently performed 1
- However, at 491 µg/g, persistently elevated levels likely indicate true inflammation requiring action 1
Important Caveats
False Positives
At this level (>250 µg/g), the false positive rate is approximately 14-21% depending on your recent endoscopic history 1. This means there's a small chance you could be in endoscopic remission despite this elevation, which is why direct visualization is essential.
Non-IBD Causes
Calprotectin can be elevated in:
- Gastrointestinal infections
- Ischemic colitis
- Colorectal neoplasia
- Recent gastrointestinal surgery (particularly esophagogastric procedures) 5
- NSAIDs use
Prognostic Significance
If left unaddressed, elevated calprotectin at this level is associated with disease progression, hospitalization, and need for surgery in Crohn's disease patients 6. The median calprotectin in patients who experienced disease progression was 432 µg/g—very close to your level 6.
Treatment Implications
Do not adjust therapy empirically. The evidence strongly supports endoscopic confirmation before treatment escalation 1. Once endoscopy confirms active inflammation:
- Treatment should be optimized or switched
- Aim for calprotectin <150 µg/g (ideally <50 µg/g for complete mucosal healing) 1, 4
- Monitor calprotectin every 2-4 months during active treatment, then every 6-12 months once in remission 1
The goal is disease clearance (endoscopic and histologic remission), which is associated with better long-term outcomes including reduced relapse, surgery, and cancer risk 7.